by Katie Hogan | Jun 4, 2026 | AI
A recent Wharton experiment found that AI assistance can hurt users substantially when the AI is wrong. When AI gave correct answers, AI-assisted users outperformed an unassisted control. When AI gave wrong answers, AI-assisted users performed substantially worse than...
by Katie Hogan | May 19, 2026 | Market Access
| Author: Alison Kneen, Global Market Access Practice Lead, BioVid Geopolitics is crucial to understand in today’s pharmaceutical market. This week saw the White House claim that their Most Favored Nation (MFN) policy was going to create potential savings of $529...
by Katie Hogan | Apr 29, 2026 | Oncology
Why an Oncology CoE? Because Complexity Has Outpaced Human Capacity. A widening synthesis gap – the distance between the overwhelming volume of clinical data and a team’s ability to translate it into a winning strategy – is the real challenge in oncology...
by Katie Hogan | Apr 8, 2026 | Insights
Patients can’t fully explain their own health decisions. Much of the processing happens before conscious thought, and standard research misses the visceral layer driving the decisions that matter most. The Missing System Kahneman’s System 1 (fast,...
by Katie Hogan | Mar 26, 2026 | Oncology
For decades, oncology has pursued the ‘magic bullet,’ precision therapies that selectively eradicate tumors while sparing healthy tissue. Antibody-drug conjugates (ADCs) are among the closest realizations of that vision. Yet as the pipeline saturates, a new...
